A Certificate of Analysis should reduce uncertainty about material. The document must read as a chain of evidence: one report, one sample, one lot, identified procedures, and clear results. A purity percentage without that chain is only an isolated number.
Reviewing a peptide COA in a fixed order makes gaps easier to detect. First establish that the report is genuine and belongs to the received lot. Then evaluate what each test measured. Only after those steps should the laboratory decide whether the available evidence meets its protocol.
1. Establish the Report-to-Vial Match
Compare the material name and batch or lot code on the COA with the vial label, receiving record, and inventory system. All four should point to the same material. A similar product name is not enough, especially when several strengths, sequences, or lots may exist.
Do not substitute the report number, Sample ID, or Internal Lab ID for the production batch unless the documentation explicitly defines that relationship. Those identifiers normally track the certificate and laboratory submission. If the lot link cannot be demonstrated, quarantine the document from the decision and request a corrected or traceable copy.
2. Verify Source, Dates, and Authorization
Identify the testing laboratory and use a direct verification channel when one is available. A laboratory-hosted report portal, controlled QR destination, or confirmation from published contact information carries more weight than a screenshot or detached image. Check the report's completion or release date and the name or role authorizing it.
Received, analysis, completion, and release dates are not interchangeable. Together they help reconstruct the testing sequence, but no single date creates a universal shelf life for the data. Continued relevance depends on stability evidence, storage conditions, material history, and the study's acceptance rules.
Check for amendments as well. A corrected batch field, recalculated result, or changed interpretation should appear in an authorized revision rather than an informal annotation. The active quality record should identify which version governs the lot and why any earlier issue was superseded.
3. Assign the Correct Meaning to Each Result
| Attribute | Primary question | Common overreach |
|---|---|---|
| Identity | Does evidence support the named compound? | Assuming identity from the label |
| Purity | What fraction is the main component under this method? | Treating area percent as vial content |
| Assay/content | How much target material was measured? | Assuming it characterizes every impurity |
These outputs complement one another but cannot be used as synonyms. A sample can show a high relative purity and still differ from its stated amount. A correct measured mass does not prove molecular identity. Build the interpretation from the result's units, calculation basis, and analytical purpose.
4. Inspect the Analytical Method, Not Just the Instrument
“HPLC tested” or “MS tested” is too broad to define a conclusion. The certificate should identify the test and preferably reference a controlled procedure. For chromatography, selectivity, reference materials, detector conditions, integration, and separation from nearby components affect the meaning of a purity or assay value. For mass spectrometry, the observed mass and acceptance basis should be clear enough to support the identity claim.
When one procedure cannot distinguish the target from likely interferences, a second method based on another measurement principle may be needed. Method fitness is tied to the analytical question; it is not guaranteed by an instrument's sophistication.
Reference standards and controls help anchor that judgment. Determine whether the comparison material was suitably characterized and whether system suitability was demonstrated for the run. These details may reside in supporting data rather than the summary certificate, but they become important when the protocol requires independent technical review.
5. Map the Boundaries of the Certificate
List the attributes required by the protocol, then mark which ones appear on the COA. Purity reporting does not silently include sterility, endotoxin, water, counterions, residual solvents, aggregation, or microbial testing. If the document does not state an attribute and result, treat it as outside the certificate's demonstrated scope.
The same discipline applies to specifications. A numerical result can be informative, but a pass designation should connect to a stated acceptance limit. Avoid importing universal thresholds from another compound, supplier, or method. Specifications must be defined for the material and intended analytical use.
6. Make and Record the Acceptance Decision
Close the review with a short, reproducible checklist: authentic source, exact lot match, clear compound designation, relevant test methods, units, limits, numerical results, authorization, and no unresolved contradictions. If the protocol requires an attribute that was not measured, obtain the missing evidence or document why the material is not accepted.
If two fields conflict, do not select the more convenient one. Place the material on hold and resolve the discrepancy with the issuing source. A documented hold protects the study from silent substitutions while preserving a clear record of how the final disposition was reached.
Guidance written for regulated pharmaceutical materials can illustrate strong reporting practice, but an RUO certificate should not be presented as regulatory approval or proof of clinical suitability. The correct conclusion is narrower: this identified laboratory reported these results for this traceable sample using these stated procedures. That precision is what makes a COA operationally useful.